-
-
-
-
-
-
-
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt, Germany for Contrave in Latin America
-
-
-
-
-
-
-
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017
-
-
-
-
-
-
-
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Bruno Farmaceutici S.p.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy
-
-
-
-
-
-
-
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Consilient Health Ltd. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in the UK and Ireland
-
-
-
-
-
-
-
Orexigen Therapeutics (OREX) Misses Q2 EPS by 26c
-
-
-
-
-
-
-
Orexigen (OREX) Names Tom Cannell as COO and Jason Keyes as CFO
-
-
-
-
-
-
-
Orexigen Therapeutics (OREX) Tops Q1 EPS by 2c, Sales Miss
-
929,665 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All